Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOTUM | Q6P988 | 3/20 | 0.58 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.44 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.44 |
| ▸ | MAPT | P10636 | 2/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | HTT | P42858 | 1/20 | 0.42 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.42 |
| ▸ | CA12 | O43570 | 1/20 | 0.41 |
| ▸ | CA1 | P00915 | 1/20 | 0.41 |
| ▸ | CA2 | P00918 | 1/20 | 0.41 |
| ▸ | CA7 | P43166 | 1/20 | 0.41 |
| ▸ | XDH | P47989 | 1/20 | 0.41 |
| ▸ | CA9 | Q16790 | 1/20 | 0.41 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.41 |
| ▸ | MRGPRX4 | Q96LA9 | 3/20 | 0.41 |
| ▸ | RXRA | P19793 | 1/20 | 0.40 |
| ▸ | HNF4A | P41235 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2801973 | 0.89 | NOTUM (0.53) | NOTUMKDM4EMAPTALDH1A1LMNA | |
| SCHEMBL8162414 | 0.89 | NOTUM (0.62) | NOTUMCYP1A2CYP2C9KDM4EMAPT | |
| SCHEMBL2805750 | 0.87 | MAPT (0.50) | NOTUMCYP2C9KDM4EMAPTALDH1A1 | |
| SCHEMBL18952402 | 0.86 | HSD17B2 (0.49) | NOTUMCYP1A2KDM4EMAPTALDH1A1 | |
| SCHEMBL980319 | 0.86 | NOTUM (0.52) | NOTUMKDM4EMAPTALDH1A1LMNA | |
| SCHEMBL2802155 | 0.86 | NOTUM (0.52) | NOTUMKDM4EMAPTALDH1A1LMNA | |
| SCHEMBL16533323 | 0.84 | MAPT (0.59) | NOTUMCYP1A2CYP2C9KDM4EMAPT | |
| SCHEMBL4275295 | 0.84 | MAPT (0.59) | NOTUMCYP1A2CYP2C9KDM4EMAPT | |
| SCHEMBL10088909 | 0.84 | NOTUM (0.56) | NOTUMCYP1A2CYP2C9KDM4EMAPT | |
| SCHEMBL1932761 | 0.84 | L3MBTL1 (0.51) | KDM4EALDH1A1HTTL3MBTL1CA12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 62 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12528802-B2 | Heterocyclic compound | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2026-01-20 | — | — | US | disclosed |
| US-20220274982-A1 | HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2022-09-01 | — | — | US | disclosed |
| EP-4005638-A1 | HETEROCYCLIC COMPOUND | Takeda Pharmaceutical Company Limited (JP) | 2022-06-01 | — | — | EP | disclosed |
| US-9663510-B2 | Substituted triazolopyridines and their use as TTK inhibitors | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2017-05-30 | — | — | US | disclosed |
| US-9663510-B2 | Substituted triazolopyridines and their use as TTK inhibitors | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2017-05-30 | — | — | US | disclosed |
| US-9663510-B2 | Substituted triazolopyridines and their use as TTK inhibitors | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2017-05-30 | — | — | US | disclosed |
| US-9555022-B2 | Substituted triazolopyridines | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2017-01-31 | — | — | US | disclosed |
| US-9555022-B2 | Substituted triazolopyridines | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2017-01-31 | — | — | US | disclosed |
| US-9555022-B2 | Substituted triazolopyridines | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2017-01-31 | — | — | US | disclosed |
| US-20160264568-A1 | SUBSTITUTED TRIAZOLOPYRIDINES HAVING ACTIVITY AS MPS-1 INHIBITORS | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2016-09-15 | — | — | US | disclosed |
| EP-2507236-A1 | TRIAZOLOPYRIDINE DERIVATIVES | Bayer Intellectual Property GmbH (DE) | 2012-10-10 | — | — | EP | disclosed |
| WO-2011157688-A1 | SUBSTITUTED TRIAZOLOPYRIDINES | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2011-12-22 | — | — | WO | disclosed |
| WO-2011157688-A1 | SUBSTITUTED TRIAZOLOPYRIDINES | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2011-12-22 | — | — | WO | disclosed |
| WO-2011064328-A1 | TRIAZOLOPYRIDINE DERIVATIVES | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2011-06-03 | — | — | WO | disclosed |
| WO-2011064328-A1 | TRIAZOLOPYRIDINE DERIVATIVES | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2011-06-03 | — | — | WO | disclosed |
| WO-2010132016-A1 | BIS-(SULFONYLAMINO) DERIVATIVES FOR TREATMENT OF PAIN AND INFLAMMATION | ASTRAZENECA AB (SE) | 2010-11-18 | — | — | WO | disclosed |
| WO-2010132016-A1 | BIS-(SULFONYLAMINO) DERIVATIVES FOR TREATMENT OF PAIN AND INFLAMMATION | ASTRAZENECA AB (SE) | 2010-11-18 | — | — | WO | disclosed |
| US-20100292279-A1 | Bis-(Sulfonylamino) Derivatives in Therapy | ASTRAZENECA AB (SE) | 2010-11-18 | — | — | US | disclosed |
| US-20100292279-A1 | Bis-(Sulfonylamino) Derivatives in Therapy | ASTRAZENECA AB (SE) | 2010-11-18 | — | — | US | disclosed |
| US-20100292279-A1 | Bis-(Sulfonylamino) Derivatives in Therapy | ASTRAZENECA AB (SE) | 2010-11-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160264568-A1 | SUBSTITUTED TRIAZOLOPYRIDINES HAVING ACTIVITY AS MPS-1 INHIBITORS | CMA1, TPP1, TPSAB1 | NOTUM 1486/4885CYP1A2 624/4885CYP2C9 1027/4885 |
| US-12528802-B2 | Heterocyclic compound | GBA2, GBA1, GALC | NOTUM 1362/4885CYP1A2 3874/4885CYP2C9 4727/4885 |
| US-20220274982-A1 | HETEROCYCLIC COMPOUND | GBA1, GBA2, GALC | NOTUM 655/4885CYP1A2 2998/4885CYP2C9 4684/4885 |
| US-20100292279-A1 | Bis-(Sulfonylamino) Derivatives in Therapy | PTGER1, SULT2A1, SULT1E1 | NOTUM 954/4885CYP1A2 25/4885CYP2C9 35/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.